v3.25.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2025
Segment Information  
Schedule of segment revenue, segment loss, and significant segment expenses

Three Months Ended March 31, 

2025

2024

Revenue

3,120

2,972

Cost of revenue

1,517

1,467

Program expenses (1)

YUTREPIA

9,758

6,630

L606

3,268

1,578

Generic Treprostinil

151

203

Total program expenses

13,177

8,411

Non-program expenses (2)

 

3,770

 

6,350

Personnel, including stock-based compensation

20,081

15,545

Loss from operations

 

(35,425)

 

(28,801)

Other income (expense), net

 

(2,942)

 

(1,282)

Net loss

 

(38,367)

 

(30,083)

(1)Includes external research and development and general and administrative expenses
(2)Includes professional service fees, facilities & infrastructure expenses, insurance, depreciation & amortization, and other corporate expenses